CinCor Pharma, Inc., (CINC) News
Filter CINC News Items
CINC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CINC News Highlights
- For CINC, its 30 day story count is now at 2.
- Over the past 26 days, the trend for CINC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CINC are DRUG.
Latest CINC News From Around the Web
Below are the latest news stories about CINCOR PHARMA INC that investors may wish to consider to help them evaluate CINC as an investment opportunity.
CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of BaxdrostatWALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor” or the “Company”) announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) on the anticipated Phase 3 program for baxdrostat in hypertension. Baxdrostat is a once daily potentially first-in-class, highly selective aldosterone synthase inhibitor. On February 17, 2023, the Company received the official meeting minutes from the End-of-Phase 2 meeting with the FDA held on |
CinCor CEO: acquisition by AstraZeneca was more than a year in the makingBefore CinCor Pharma Inc. agreed to a $1.8 billion acquisition by AstraZeneca plc, it turned down several other offers from the U.K. pharmaceutical giant. |
Why These Two Biotech Stocks Blasted Higher This WeekTwo somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca, while Albireo Pharma (NASDAQ: ALBO) is set to be owned by France-based peer Ipsen. Both of these deals are very lucrative, to the point where CinCor's stock rocketed 146% over the course of the week, and Albireo shot 92% skyward, according to data compiled by S&P Global Market Intelligence. |
Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & MoreUpdates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week. |
AstraZeneca Stock Nabs Brief Breakout After $1.8 Billion CinCor BuyoutAstraZeneca stock briefly broke out on Tuesday, a day after announcing its $1.8 billion plan to acquire CinCor. |
AstraZeneca (AZN) Set to Acquire CinCor Pharma for $1.3BAstraZeneca's (AZN) CinCor Pharma buyout is going to add blood pressure drug baxdrostat to its cardiorenal pipeline. |
Stocks Building Off Of Friday's RallyThe Dow Jones Industrial Average is up more than 280 points midday, while the Nasdaq Composite Index is also up triple digits. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning! |
Why Is CinCor (CINC) Stock Up 138% Today?CinCor (CINC) stock is rocketing higher on Monday following news that AstraZeneca (AZN) is acquiring the company for up to $1.8 billion. |
AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion DealAstraZeneca said it has agreed to buy CinCor Pharma, maker of clinical-stage blood pressure drug baxdrostat, in a deal valued at $1.8 billion. |